

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Aeterna Zentaris Inc.  
Form 6-K  
March 30, 2006

FORM 6-K  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER  
-----

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of March 2006

AETERNA ZENTARIS INC.  
-----

1405, boul. du Parc-Technologique  
Quebec, Quebec  
Canada, G1P 4P5  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F.

Form 20-F                      Form 40-F                      X  
-----                                      -----

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes                      No                      X  
-----                                      -----

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g3-2(b): 82-\_\_\_\_\_

DOCUMENTS INDEX  
-----

Documents Description  
-----

- 1. Press release dated March 28, 2006: Aeterna Zentaris to Present Results  
of Three Preclinical Trials at the American Association for Cancer  
Research (AACR) Meeting in Washington  
-----

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

[AETERNA ZENTARIS LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.  
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881  
www.aeternazentaris.com

PRESS RELEASE  
For immediate release

AETERNA ZENTARIS TO PRESENT RESULTS OF THREE PRECLINICAL TRIALS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) MEETING IN WASHINGTON

QUEBEC CITY, CANADA, MARCH 28, 2006 - AETerna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) today announced that it will present abstracts outlining results of three preclinical trials for multiple cancers in the Exhibition Hall of the Washington Convention Center during the American Association for Cancer Research Annual Meeting, which will be held from April 1-5, 2006, in Washington D.C.

On Sunday, April 2, from 8 am to noon (ET), AETerna Zentaris will present abstract #499, "A NEW HIGHLY POTENT CYTOTOXIC COMPOUND WITH INHIBITORY EFFECTS ON TUBULIN POLYMERIZATION AND TOPOISOMERASE II", with respect to ZEN-012/ZEN-017 as a potential treatment for breast, colon and skin cancer, as well as leukemia.

On Monday, April 3, from 1 pm to 5 pm (ET), abstract #3082, "TARGETED THERAPY OF GYNECOLOGICAL TUMORS WITH CYTOTOXIC PEPTIDE ANALOGS", will outline preclinical results on cytotoxic conjugates for gynaecological cancers.

Lastly, on Tuesday, April 4, from 8 am to noon (ET), the Company will present abstract #3808, "NOVEL PYRIDOPYRAZINE-UREA DERIVATIVES ARE HIGHLY SELECTIVE DUAL MECHANISM INHIBITORS OF PI3K AND ERK1/2", relating to preclinical results on signal transduction inhibitors in breast, colon and pancreatic cancer.

ABOUT AETERNA ZENTARIS INC.

AETerna Zentaris Inc. is a growing global biopharmaceutical company engaged in the discovery, development and marketing of therapies for cancer and endocrine disorders.

AETerna Zentaris also owns 48.4% of the equity of Atrium Biotechnologies Inc. (TSX: ATB.sv) and 64.8% of its voting rights. Atrium is a developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutritional industries.

News releases and additional information are available at  
www.aeternazentaris.com.

-----

[AETERNA ZENTARIS LOGO]

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

-30-

CONTACTS

MEDIA RELATIONS

Paul Burroughs  
(418) 652-8525 ext. 406  
paul.burroughs@aeternazentaris.com  
-----

INVESTOR RELATIONS

Jenene Thomas  
(418) 655-6420 or  
(908) 996-3154  
jenene.thomas@aeternazentaris.com  
-----

2

SIGNATURE  
-----

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: March 29, 2006  
-----

By: /s/ Mario Paradis  
-----

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Mario Paradis  
Senior Finance Director and Corporate Secretary